These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 11145701)

  • 1. Role of C5a in multiorgan failure during sepsis.
    Huber-Lang M; Sarma VJ; Lu KT; McGuire SR; Padgaonkar VA; Guo RF; Younkin EM; Kunkel RG; Ding J; Erickson R; Curnutte JT; Ward PA
    J Immunol; 2001 Jan; 166(2):1193-9. PubMed ID: 11145701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement-induced impairment of innate immunity during sepsis.
    Huber-Lang MS; Younkin EM; Sarma JV; McGuire SR; Lu KT; Guo RF; Padgaonkar VA; Curnutte JT; Erickson R; Ward PA
    J Immunol; 2002 Sep; 169(6):3223-31. PubMed ID: 12218141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for a functional role of the second C5a receptor C5L2.
    Gao H; Neff TA; Guo RF; Speyer CL; Sarma JV; Tomlins S; Man Y; Riedemann NC; Hoesel LM; Younkin E; Zetoune FS; Ward PA
    FASEB J; 2005 Jun; 19(8):1003-5. PubMed ID: 15784721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Divergent signaling pathways in phagocytic cells during sepsis.
    Guo RF; Riedemann NC; Sun L; Gao H; Shi KX; Reuben JS; Sarma VJ; Zetoune FS; Ward PA
    J Immunol; 2006 Jul; 177(2):1306-13. PubMed ID: 16818791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in the novel orphan, C5a receptor (C5L2), during experimental sepsis and sepsis in humans.
    Huber-Lang M; Sarma JV; Rittirsch D; Schreiber H; Weiss M; Flierl M; Younkin E; Schneider M; Suger-Wiedeck H; Gebhard F; McClintock SD; Neff T; Zetoune F; Bruckner U; Guo RF; Monk PN; Ward PA
    J Immunol; 2005 Jan; 174(2):1104-10. PubMed ID: 15634936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-complement strategies in experimental sepsis.
    Ward PA; Riedemann NC; Guo RF; Huber-Lang M; Sarma JV; Zetoune FS
    Scand J Infect Dis; 2003; 35(9):601-3. PubMed ID: 14620141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effects of C5a blockade in sepsis.
    Czermak BJ; Sarma V; Pierson CL; Warner RL; Huber-Lang M; Bless NM; Schmal H; Friedl HP; Ward PA
    Nat Med; 1999 Jul; 5(7):788-92. PubMed ID: 10395324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of C5 activation products in sepsis.
    Ward PA
    ScientificWorldJournal; 2010 Dec; 10():2395-402. PubMed ID: 21170490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation by C5a of neutrophil activation during sepsis.
    Riedemann NC; Guo RF; Bernacki KD; Reuben JS; Laudes IJ; Neff TA; Gao H; Speyer C; Sarma VJ; Zetoune FS; Ward PA
    Immunity; 2003 Aug; 19(2):193-202. PubMed ID: 12932353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression.
    Riedemann NC; Neff TA; Guo RF; Bernacki KD; Laudes IJ; Sarma JV; Lambris JD; Ward PA
    J Immunol; 2003 Jan; 170(1):503-7. PubMed ID: 12496437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo regulation of neutrophil apoptosis by C5a during sepsis.
    Guo RF; Sun L; Gao H; Shi KX; Rittirsch D; Sarma VJ; Zetoune FS; Ward PA
    J Leukoc Biol; 2006 Dec; 80(6):1575-83. PubMed ID: 16997861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of C5a-C5aR interaction in sepsis.
    Guo RF; Riedemann NC; Ward PA
    Shock; 2004 Jan; 21(1):1-7. PubMed ID: 14676676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effects of anti-C5a peptide antibodies in experimental sepsis.
    Huber-Lang MS; Sarma JV; McGuire SR; Lu KT; Guo RF; Padgaonkar VA; Younkin EM; Laudes IJ; Riedemann NC; Younger JG; Ward PA
    FASEB J; 2001 Mar; 15(3):568-70. PubMed ID: 11259369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-function relationships of human C5a and C5aR.
    Huber-Lang MS; Sarma JV; McGuire SR; Lu KT; Padgaonkar VA; Younkin EM; Guo RF; Weber CH; Zuiderweg ER; Zetoune FS; Ward PA
    J Immunol; 2003 Jun; 170(12):6115-24. PubMed ID: 12794141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C5a, a therapeutic target in sepsis.
    Guo RF; Ward PA
    Recent Pat Antiinfect Drug Discov; 2006 Jan; 1(1):57-65. PubMed ID: 18221134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection of innate immunity by C5aR antagonist in septic mice.
    Huber-Lang MS; Riedeman NC; Sarma JV; Younkin EM; McGuire SR; Laudes IJ; Lu KT; Guo RF; Neff TA; Padgaonkar VA; Lambris JD; Spruce L; Mastellos D; Zetoune FS; Ward PA
    FASEB J; 2002 Oct; 16(12):1567-74. PubMed ID: 12374779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of the Complement Alternative Pathway in Serum Chemotactic Activity During Sepsis.
    Xu G; Feng Y; Li D; Zhou Q; Chao W; Zou L
    Shock; 2018 Oct; 50(4):435-441. PubMed ID: 29040213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered neutrophil trafficking during sepsis.
    Guo RF; Riedemann NC; Laudes IJ; Sarma VJ; Kunkel RG; Dilley KA; Paulauskis JD; Ward PA
    J Immunol; 2002 Jul; 169(1):307-14. PubMed ID: 12077259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis.
    Laudes IJ; Chu JC; Sikranth S; Huber-Lang M; Guo RF; Riedemann N; Sarma JV; Schmaier AH; Ward PA
    Am J Pathol; 2002 May; 160(5):1867-75. PubMed ID: 12000738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel C5a-neutralizing mirror-image (l-)aptamer prevents organ failure and improves survival in experimental sepsis.
    Hoehlig K; Maasch C; Shushakova N; Buchner K; Huber-Lang M; Purschke WG; Vater A; Klussmann S
    Mol Ther; 2013 Dec; 21(12):2236-46. PubMed ID: 23887360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.